Sakti Chakrabarti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3152918/publications.pdf

Version: 2024-02-01

35 papers	617 citations	933447 10 h-index	677142 22 g-index
36 all docs	36 docs citations	36 times ranked	900 citing authors

#	Article	IF	Citations
1	Does detection of microsatellite instability-high (MSI-H) by plasma-based testing predict tumor response to immunotherapy (IO) in patients with pancreatic cancer (PC)?. Journal of Clinical Oncology, 2022, 40, 607-607.	1.6	3
2	A glimpse into the future of esophageal carcinoma in the United States: Predicting the future incidence based on the current epidemiological data.. Journal of Clinical Oncology, 2022, 40, 248-248.	1.6	0
3	Definitive chemoradiation for oligometastatic esophageal cancer patients.. Journal of Clinical Oncology, 2022, 40, 359-359.	1.6	0
4	Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 85-98.	3.3	12
5	Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Cancers, 2022, 14, 2588.	3.7	7
6	Successful infusional 5-fluorouracil administration in a patient with vasospastic angina. American Heart Journal Plus, 2022, , 100147.	0.6	0
7	Organ Preservation in Colon Cancer: An Illustrative Case Report. Cureus, 2022, , .	0.5	0
8	Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)â€"Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC). Cancers, 2022, 14, 3078.	3.7	10
9	Definitive chemoradiotherapy +/- induction chemotherapy in esophageal cancer: A real-world experience.. Journal of Clinical Oncology, 2022, 40, e16072-e16072.	1.6	0
10	Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. , 2022, 10, e004485.		16
11	Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precision Oncology, 2022, , .	3.0	4
12	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. European Journal of Cancer, 2021, 144, 101-112.	2.8	18
13	Outcomes on <scp>antiâ€VEGFR</scp>â€2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. International Journal of Cancer, 2021, 149, 378-386.	5.1	14
14	A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy. Cureus, 2021, 13, e14640.	0.5	4
15	TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies. , 2021, 224, 107823.		10
16	Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. Surgical Oncology Clinics of North America, 2021, 30, 673-691.	1.5	1
17	Comment on: development and external validation of a model to predict overall survival in patients with resected gallbladder cancer. Hepatobiliary Surgery and Nutrition, 2021, 11, 0-0.	1.5	0
18	Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist, 2020, 25, 380-e763.	3.7	10

#	Article	IF	Citations
19	The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review. Cancers, 2020, 12, 2808.	3.7	33
20	Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm. Cancers, 2020, 12, 2039.	3.7	52
21	Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World Journal of Gastrointestinal Oncology, 2020, 12, 808-832.	2.0	59
22	Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2019, 10, 554-561.	1.4	31
23	Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC). Annals of Oncology, 2019, 30, v280.	1.2	0
24	Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. Journal of Gastrointestinal Oncology, 2019, 10, 171-178.	1.4	20
25	Intratumoral CD3+ and CD8+ T-Cell Densities in Patients With DNA Mismatch Repairâ€“Deficient Metastatic Colorectal Cancer Receiving Programmed Cell Death-1 Blockade. JCO Precision Oncology, 2019, 3, 1-7.	3.0	9
26	Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. Clinical Colorectal Cancer, 2019, 18, 52-57.	2.3	32
27	Intratumoral CD3+ and CD8+ T-cell densities in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC) receiving programmed death-1 (PD-1) blockade.. Journal of Clinical Oncology, 2019, 37, 3532-3532.	1.6	2
28	Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.. Journal of Clinical Oncology, 2019, 37, 393-393.	1.6	0
29	How I Treat Metastatic Colorectal Cancer With Maintenance Therapies. , 2019, , .		0
30	First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. Oncologist, 2018, 23, 840-843.	3.7	11
31	5-fluorouracil and cardiotoxicity: a review. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878014.	3.2	255
32	Safety and tolerability of the bolus 5-fluorouracil (5-FU) based FLOX and IFL regimens in patients who developed fluoropyrimidine-induced coronary vasospasm during therapy with infusional 5-FU or capecitabine.. Journal of Clinical Oncology, 2018, 36, e15513-e15513.	1.6	1
33	Local excision for stage I anal canal squamous cell carcinoma (ACSCC): A case series from Mayo Clinic.. Journal of Clinical Oncology, 2018, 36, 864-864.	1.6	0
34	Clinical outcome of patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) treated with pembrolizumab.. Journal of Clinical Oncology, 2018, 36, e24127-e24127.	1.6	1
35	Curative intent of local excision alone for stage I anal canal squamous cell carcinoma (ACSCC).. Journal of Clinical Oncology, 2018, 36, e15574-e15574.	1.6	0